Search
Tesidolumab
go.drugbank.com/drugs/DB11926InvestigationalTesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration
QR-1123
go.drugbank.com/drugs/DB17869InvestigationalQR-1123 is a first-in-class investigational RNA-based oligonucleotide designed to treat autosomal dominant retinitis pigmentosa due to the P23H mutation in the rhodopsin (_RHO_) gene.[L46782]
Varespladib methyl
go.drugbank.com/drugs/DB05737InvestigationalStudies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.
Lexacalcitol
go.drugbank.com/drugs/DB03451ExperimentalIt is known to target the vitamin D3 receptor. … This compound belongs to the vitamin D and derivatives class of chemicals. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
Itepekimab
go.drugbank.com/drugs/DB16206InvestigationalItepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe
Hesperetin
go.drugbank.com/drugs/DB01094InvestigationalHesperetin belongs to the flavanone class of flavonoids. Hesperetin, in the form of its glycoside [hesperidin], is the predominant flavonoid in lemons and oranges.
Itolizumab
go.drugbank.com/drugs/DB16207InvestigationalItolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Elezanumab
go.drugbank.com/drugs/DB15240InvestigationalElezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis).
Afabicin
go.drugbank.com/drugs/DB15268InvestigationalAfabicin is under investigation in clinical trial NCT03723551 (Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus